Fintel reports that on November 10, 2023, Wells Fargo upgraded their outlook for Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Equal-Weight .
Analyst Price Forecast Suggests 122.75% Upside
As of October 31, 2023, the average one-year price target for Celldex Therapeutics is 60.01. The forecasts range from a low of 21.21 to a high of $76.65. The average price target represents an increase of 122.75% from its latest reported closing price of 26.94.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Celldex Therapeutics is 1MM, a decrease of 67.29%. The projected annual non-GAAP EPS is -2.48.
What is the Fund Sentiment?
There are 377 funds or institutions reporting positions in Celldex Therapeutics. This is a decrease of 21 owner(s) or 5.28% in the last quarter. Average portfolio weight of all funds dedicated to CLDX is 0.19%, an increase of 1.00%. Total shares owned by institutions decreased in the last three months by 0.59% to 53,429K shares. 
The put/call ratio of CLDX is 1.22, indicating a bearish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 5,131K shares representing 10.86% ownership of the company. In it's prior filing, the firm reported owning 4,182K shares, representing an increase of 18.51%. The firm increased its portfolio allocation in CLDX by 10.43% over the last quarter.
Rtw Investments holds 3,463K shares representing 7.33% ownership of the company. In it's prior filing, the firm reported owning 3,084K shares, representing an increase of 10.94%. The firm decreased its portfolio allocation in CLDX by 3.19% over the last quarter.
Kynam Capital Management holds 2,600K shares representing 5.50% ownership of the company. In it's prior filing, the firm reported owning 1,409K shares, representing an increase of 45.79%. The firm increased its portfolio allocation in CLDX by 85.34% over the last quarter.
Polar Capital Holdings holds 2,417K shares representing 5.11% ownership of the company. In it's prior filing, the firm reported owning 2,268K shares, representing an increase of 6.16%. The firm decreased its portfolio allocation in CLDX by 4.91% over the last quarter.
Bellevue Group holds 1,800K shares representing 3.81% ownership of the company. No change in the last quarter.
Celldex Therapeutics Background Information
(This description is provided by the company.)
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
